RT Journal Article
SR Electronic
T1 Acute Kidney Injury in Hospitalized Patients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.04.20090944
DO 10.1101/2020.05.04.20090944
A1 Chan, Lili
A1 Chaudhary, Kumardeep
A1 Saha, Aparna
A1 Chauhan, Kinsuk
A1 Vaid, Akhil
A1 Baweja, Mukta
A1 Campbell, Kirk
A1 Chun, Nicholas
A1 Chung, Miriam
A1 Deshpande, Priya
A1 Farouk, Samira S.
A1 Kaufman, Lewis
A1 Kim, Tonia
A1 Koncicki, Holly
A1 Lapsia, Vijay
A1 Leisman, Staci
A1 Lu, Emily
A1 Meliambro, Kristin
A1 Menon, Madhav C.
A1 Rein, Joshua L.
A1 Sharma, Shuchita
A1 Tokita, Joji
A1 Uribarri, Jaime
A1 Vassalotti, Joseph A.
A1 Winston, Jonathan
A1 Mathews, Kusum S.
A1 Zhao, Shan
A1 Paranjpe, Ishan
A1 Somani, Sulaiman
A1 Richter, Felix
A1 Do, Ron
A1 Miotto, Riccardo
A1 Lala, Anuradha
A1 Kia, Arash
A1 Timsina, Prem
A1 Li, Li
A1 Danieletto, Matteo
A1 Golden, Eddye
A1 Glowe, Patricia
A1 Zweig, Micol
A1 Singh, Manbir
A1 Freeman, Robert
A1 Chen, Rong
A1 Nestler, Eric
A1 Narula, Jagat
A1 Just, Allan C.
A1 Horowitz, Carol
A1 Aberg, Judith
A1 Loos, Ruth J.F.
A1 Cho, Judy
A1 Fayad, Zahi
A1 Cordon-Cardo, Carlos
A1 Schadt, Eric
A1 Levin, Matthew A.
A1 Reich, David L.
A1 Fuster, Valentin
A1 Murphy, Barbara
A1 He, John Cijiang
A1 Charney, Alexander W.
A1 Böttinger, Erwin P.
A1 Glicksberg, Benjamin S.
A1 Coca, Steven G.
A1 Nadkarni, Girish N.
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/05/08/2020.05.04.20090944.abstract
AB Importance Preliminary reports indicate that acute kidney injury (AKI) is common in coronavirus disease (COVID)-19 patients and is associated with worse outcomes. AKI in hospitalized COVID-19 patients in the United States is not well-described.Objective To provide information about frequency, outcomes and recovery associated with AKI and dialysis in hospitalized COVID-19 patients.Design Observational, retrospective study.Setting Admitted to hospital between February 27 and April 15, 2020.Participants Patients aged ≥18 years with laboratory confirmed COVID-19Exposures AKI (peak serum creatinine increase of 0.3 mg/dL or 50% above baseline).Main Outcomes and Measures Frequency of AKI and dialysis requirement, AKI recovery, and adjusted odds ratios (aOR) with mortality. We also trained and tested a machine learning model for predicting dialysis requirement with independent validation.Results A total of 3,235 hospitalized patients were diagnosed with COVID-19. AKI occurred in 1406 (46%) patients overall and 280 (20%) with AKI required renal replacement therapy. The incidence of AKI (admission plus new cases) in patients admitted to the intensive care unit was 68% (553 of 815). In the entire cohort, the proportion with stages 1, 2, and 3 AKI were 35%, 20%, 45%, respectively. In those needing intensive care, the respective proportions were 20%, 17%, 63%, and 34% received acute renal replacement therapy. Independent predictors of severe AKI were chronic kidney disease, systolic blood pressure, and potassium at baseline. In-hospital mortality in patients with AKI was 41% overall and 52% in intensive care. The aOR for mortality associated with AKI was 9.6 (95% CI 7.4-12.3) overall and 20.9 (95% CI 11.7-37.3) in patients receiving intensive care. 56% of patients with AKI who were discharged alive recovered kidney function back to baseline. The area under the curve (AUC) for the machine learned predictive model using baseline features for dialysis requirement was 0.79 in a validation test.Conclusions and Relevance AKI is common in patients hospitalized with COVID-19, associated with worse mortality, and the majority of patients that survive do not recover kidney function. A machine-learned model using admission features had good performance for dialysis prediction and could be used for resource allocation.Question What is incidence and outcomes of acute kidney injury (AKI) in patients hospitalized with COVID-19?Findings In this observational study of 3,235 hospitalized patients with COVID-19 in New York City, AKI occurred in 46% of patients and 20% of those patients required dialysis. AKI was associated with increased mortality. 44% of patients discharged alive had residual acute kidney disease. A machine learned predictive model using baseline features for dialysis requirement had an AUC Of 0.79.Meaning AKI was common in patients with COVID-19, associated with increased mortality, and nearly half of patients had acute kidney disease on discharge.Competing Interest StatementGNN, CH, BM, SGC receive financial compensation as consultants and advisory board members for RenalytixAI, and own equity in RenalytixAI. BM is a non-executive director of RenalytixAI. In the past 3 years, SGC has also received consulting fees from CHF Solutions, Takeda Pharmaceuticals, Relypsa, Bayer, Goldfinch Bio, Boehringer-Ingelheim, and inRegen. In the past 3 years GNN has also received consulting fees from AstraZeneca, Reata, GLG Consulting, BioVie and grant support from Goldfinch Bio. K.S.M. is supported by K23HL130648 from the National, Heart, Lung, and Blood Institute.Funding StatementGNN is supported by a career development award from the National Institutes of Health (NIH) (K23DK107908) and is also supported by R01DK108803, U01HG007278, U01HG009610, and U01DK116100. SGC is supported by the following grants: U01DK106962, R01DK115562, R01HL085757, U01OH011326, R01DK112258, and RRTI UG 2019.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A